Neurocrine Biosciences Files 8-K on Officer/Director Changes

Ticker: NBIX · Form: 8-K · Filed: 2025-05-30T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes, financial-statements

Related Tickers: NBIX

TL;DR

NBI leadership changes and financial updates filed today.

AI Summary

Neurocrine Biosciences, Inc. filed an 8-K on May 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.

Why It Matters

This filing provides crucial updates on the company's leadership and governance structure, which can impact strategic direction and investor confidence.

Risk Assessment

Risk Level: low — The filing is routine and reports on corporate governance and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

NEUROCRINE BIOSCIENCES, INC. (company) — Registrant
May 30, 2025 (date) — Date of earliest event reported
Delaware (jurisdiction) — State of Incorporation
6027 Edgewood Bend Court, San Diego, California 92130 (address) — Address of Principal Executive Offices
( 858 ) 617-7600 (phone_number) — Registrant's telephone number

FAQ

What specific officer or director positions were affected by the changes reported in this 8-K?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided text.

Are there any new financial statements included with this filing?

Yes, the filing explicitly states 'Financial Statements and Exhibits' are included.

What is the primary business of Neurocrine Biosciences, Inc. according to the filing?

The company is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].

When was the report filed with the SEC?

The report was filed on May 30, 2025.

What is the state of incorporation for Neurocrine Biosciences, Inc.?

The company is incorporated in Delaware.

From the Filing

0000914475-25-000139.txt : 20250530 0000914475-25-000139.hdr.sgml : 20250530 20250530160510 ACCESSION NUMBER: 0000914475-25-000139 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250530 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250530 DATE AS OF CHANGE: 20250530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 251010782 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 nbix-20250530.htm 8-K nbix-20250530 false 0000914475 0000914475 2025-05-30 2025-05-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 6027 Edgewood Bend Court San Diego, California 92130 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 617-7600 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) As previously disclosed, Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025. Dr. Roberts has served as our Chief Medical Officer for the past seven years and has agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani. In connection with this transition, we entered into an Amended and Restated Employment Agreement with Dr. Roberts (the “Amended Employment Agreement”) on May 30, 2025, to be effective upon the later of: (i) June 2, 2025, and (ii) the date on which the Company’s new Chief Medical Officer commences employment (the &#82